In FGFR3 mutant bladder/urothelial cancer and FGFR1 amplified NSCLC the selective FGFR1-3 tyrosine kinase inhibitor BGJ398 has shown partial responses and was well tolerated [30]. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.